USPTO Examiner SHAMEEM GOLAM M - Art Unit 1621

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19238297Preparation and Application of Deuterated 4-Phenyl-4-PiperidinolsJune 2025September 2025Allow300YesNo
19079211HETEROCYCLIC COMPOUND AND USE THEREOFMarch 2025July 2025Allow410YesNo
19079172HETEROCYCLIC COMPOUND AND USE THEREOFMarch 2025July 2025Allow410YesNo
19023391CALCIUM-BASED METAL-ORGANIC FRAMEWORK MATERIAL, METHOD FOR MAKING THE SAME, AND USE IN CARBON DIOXIDE CAPTUREJanuary 2025December 2025Allow1101YesNo
18955583Small Molecule Degraders and Fluorescent Probes of PXRNovember 2024November 2025Allow1121NoNo
18764540MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USESJuly 2024May 2025Allow1101YesNo
18759546cGAS ANTAGONIST COMPOUNDSJune 2024January 2026Allow1911NoNo
187348992-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEADJune 2024October 2025Allow1711NoNo
18667468COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB1 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING DISEASES AND DISORDERS CHARACTERIZED BY ABNORMAL CELLULAR ACCUMULATION OF SPHINGOLIPIDS SUCH AS SPHINGOMYELINMay 2024August 2025Allow1511NoNo
18660578PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTIONMay 2024July 2025Allow1411NoNo
18659715Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune DisordersMay 2024April 2025Allow1101YesNo
18641912FUSED TRI-CYCLIC COMPOUND AS A PDE3/PDE4 DUAL INHIBITORApril 2024February 2026Allow2110YesNo
186251302-(BENZO[D]OXAZOL-2-YL)-N'-(3,5-DICHLOROBENZOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDApril 2024July 2024Allow300YesNo
18603405NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAMEMarch 2024April 2025Allow1310NoNo
18602258PLATELET COUNT-AGNOSTIC METHODS OF TREATING MYELOFIBROSISMarch 2024November 2025Allow2011NoNo
18594885METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEAMarch 2024July 2025Abandon1601NoNo
18440576POLYMERASE INHIBITORS AND RELATED COMPOSITIONS AND METHODSFebruary 2024December 2024Allow1100NoNo
18440563SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDEFebruary 2024December 2024Allow1010NoNo
18432291Solid Oral Pharmaceutical Compositions Including Alkyl 3,4,5-Trihydroxybenzoate as a Nitrosamine InhibitorFebruary 2024March 2026Allow2500NoNo
18428286METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024June 2024Allow400NoNo
18428327METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024May 2024Allow400NoNo
18421117SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOFJanuary 2024September 2024Allow800YesNo
18416734TREATMENT OF CIRCADIAN RHYTHM DISORDERSJanuary 2024October 2024Allow900YesNo
18416748TREATMENT OF CIRCADIAN RHYTHM DISORDERSJanuary 2024September 2024Allow800NoNo
18414924N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow710NoNo
18414737N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow810NoNo
18394610(E)-2-(3-CYANO-4-ISOBUTOXYPHENYL)-N'-(SUBSTITUTED BENZYLIDENE)-4-METHYLTHIAZOLE-5-CARBOHYDRAZIDES AS ANTI-TUBERCULAR AGENTSDecember 2023July 2024Allow700YesNo
183945343,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)December 2023May 2024Allow400NoNo
183949773,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)December 2023March 2024Allow300NoNo
18543793CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1- METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKINGDecember 2023March 2024Allow300YesNo
18530782STRESS TEST AND TREATMENT OF CHRONIC KIDNEY DISEASEDecember 2023August 2024Allow800YesNo
18530774ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDSDecember 2023January 2025Allow1410NoNo
18520037HETEROCYCLIC COMPOUND AND USE THEREOFNovember 2023June 2025Abandon1900NoNo
18510888BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOFNovember 2023April 2025Allow1711NoNo
18445603Dosage Unit Form(s) Comprising BTS and BTS(OMe) For Use In Boron Neutron Capture Therapy and Methods ThereofNovember 2023July 2024Allow800YesNo
18560142COMPOSITIONS FOR USE IN THE PREVENTION AND/ OR TREATMENT OF INTELLECTUAL DISABILITY AND NEURODEGENERATIVE DISEASES IN A SUBJECT WITH DOWN SYNDROMENovember 2023January 2026Allow2700NoNo
18504164BORON-CONTAINING COMPOUND AND ELECTROLYTE ADDITIVE FOR SECONDARY BATTERY CONTAINING THE SAMENovember 2023September 2024Allow1010NoNo
18502094BORON-CONTAINING COMPOUND AND ELECTROLYTE SOLUTION ADDITIVE FOR SECONDARY BATTERY INCLUDING THE SAMENovember 2023September 2024Allow1010NoNo
18495755BORON-CONTAINING COMPOUND AND ELECTROLYTE SOLUTION ADDITIVE FOR SECONDARY BATTERY INCLUDING THE SAMEOctober 2023February 2025Allow1610NoNo
183842543,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023March 2024Allow511NoNo
183828322-(BENZO[D]OXAZOL-2-YL)-N'-(3,5-DICHLOROBENZOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow501YesNo
18382959METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUNDOctober 2023August 2024Abandon1011NoNo
18380962Immunoproteasome InhibitorsOctober 2023January 2025Allow1511NoNo
18379999N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow511YesNo
18483128A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY AND AGITATIONOctober 2023December 2024Allow1510NoNo
18377533(E)-2-(3-CYANO-4-ISOBUTOXYPHENYL)-N'-(SUBSTITUTED BENZYLIDENE)-4-METHYLTHIAZOLE-5-CARBOHYDRAZIDES AS ANTI-TUBERCULAR AGENTSOctober 2023August 2024Allow1021NoNo
18479980PHOSPHORIC ACID ESTERS, METHOD OF SYNTHETIZING THEM AND USE THEREOF AS DISPERSANTSOctober 2023February 2026Allow2901YesNo
18284226ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSIONSeptember 2023December 2025Allow2700YesNo
18372980PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDSSeptember 2023December 2024Abandon1501NoNo
183729351-CYCLOPROPYL-6-FLUORO-4-OXO-7-(4-((2-THIOXOBENZO[D]THIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTIMICROBIAL COMPOUNDSeptember 2023December 2023Allow200YesNo
18472105THERAPEUTIC COMPOUNDS AND METHODS OF USESeptember 2023May 2025Allow2011NoNo
18470029BICYCLIC CX3CR1 RECEPTOR AGONISTSSeptember 2023November 2024Allow1401NoNo
18469323ACYLOXY SUBSTITUTED PHENYL DITHIANE DERIVATIVESSeptember 2023October 2024Allow1311NoNo
18281022CRYSTALLINE FORMS, COMPOSITIONS CONTAINING SAME, AND METHODS OF THEIR USESeptember 2023December 2025Allow2700YesNo
18239892TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHAAugust 2023July 2024Allow1101NoNo
18449741OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTIONAugust 2023October 2024Allow1400NoNo
18361430AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORSJuly 2023October 2024Allow1500YesNo
18355945MANUFACTURE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] AND COMPOSITIONS THEREOFJuly 2023April 2025Allow2111YesNo
18355178METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEAJuly 2023October 2024Abandon1501NoNo
18261949PROTECTED HDAC (HISTONE DEACETYLASE) INHIBITORSJuly 2023February 2026Allow3101YesNo
18261383METHOD FOR MANUFACTURING HETEROCYCLE-CONTAINING AMINO ACID COMPOUNDJuly 2023March 2026Allow3200NoNo
18220739Antioxidant Vitamin C DerivativeJuly 2023December 2023Allow510NoNo
18346933CDK2 INHIBITORSJuly 2023September 2025Abandon2611NoNo
18218128METHOD FOR PREPARING 2,5-FURANDICARBOXYLIC ACID (FDCA) FROM FURFURALJuly 2023October 2023Allow400NoNo
18213557TARGETING OF ENDOPLASMIC RETICULUM DYSFUNCTION AND PROTEIN FOLDING STRESS TO TREAT NEUROLOGICAL CONDITIONSJune 2023July 2024Allow1310NoNo
18210763GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVESJune 2023November 2024Allow1711YesNo
18334355DIARYLHYDANTOIN COMPOUNDSJune 2023October 2024Allow1700NoNo
18206005SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOFJune 2023November 2024Abandon1710NoNo
18328242MONOACYLGLYCEROL LIPASE MODULATORSJune 2023December 2024Abandon1810NoNo
18328658BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORSJune 2023September 2024Allow1511NoNo
18204649PHARMACEUTICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING ASTHMA AND OTHER DISORDERSJune 2023June 2024Allow1211NoNo
18200431Modulators of Liver Receptor Homologue 1 (LRH-1) and UsesMay 2023April 2024Allow1101YesNo
18314560THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVESMay 2023August 2024Allow1501NoNo
18035106COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAMEMay 2023January 2026Allow3201YesNo
18032499MULTIVALENT TERPENE-BASED BOLAAMPHIPHILES FOR GENE DELIVERYApril 2023March 2026Allow3510NoNo
18031893Novel Glutamine AnalogsApril 2023November 2025Allow3101YesNo
18248176PROCESS FOR BORON-CONTAINING COMPOUNDSApril 2023December 2025Allow3201YesNo
18246777SYNTHESIS OF PYRROLE ACID DERIVATIVESMarch 2023December 2025Allow3301YesNo
17907745BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUSMarch 2023December 2025Allow3801YesNo
180280623-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONISTMarch 2023August 2025Allow2800NoNo
18187494OXYGENATED HYDROCARBON PRODUCTION SYSTEM WITH ACIDIC IMPURITY REMOVAL RESIN COLUMNMarch 2023August 2025Allow2900YesNo
18027080GLYCEROL COMPOUNDS AND METHODS OF USEMarch 2023March 2026Abandon3601NoNo
18183655TREATMENT OF CIRCADIAN RHYTHM DISORDERSMarch 2023October 2023Allow701YesNo
18120110TREPROSTINIL PRODRUGSMarch 2023August 2024Allow1700NoNo
18044219SPIROCYCLIC COMPOUND CONTAINING CATALYST FOR USE IN CATALYZING REACTION OF EPOXIDE COMPOUND AND CARBON DIOXIDEMarch 2023January 2026Allow3501YesNo
18043947NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOFMarch 2023July 2025Allow2800NoNo
18024443SULFAMOYL BENZENE DERIVATIVES AND USES THEREOFMarch 2023February 2026Abandon3501NoNo
18043646DIAZINOXIMES SCAFFOLDSMarch 2023February 2026Allow3511NoNo
18043548METHODS OF TREATING CANCERFebruary 2023December 2025Allow3410NoNo
18172024Polyethylene Glycol-Conjugated Glucocorticoid Prodrugs and Compositions and Methods ThereofFebruary 2023February 2024Allow1101NoNo
18042137FUMARATE DERIVATIVES AND THEIR MEDICAL USEFebruary 2023February 2026Abandon3601NoNo
18169702MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODSFebruary 2023July 2024Allow1711NoNo
18110260PHARMACEUTICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING ASTHMA AND OTHER DISORDERSFebruary 2023July 2023Allow500YesNo
18109705INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOFFebruary 2023June 2024Allow1611YesNo
18168128Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune DisordersFebruary 2023February 2024Allow1211NoNo
18020923BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOFFebruary 2023November 2025Allow3301YesNo
18019875INOTODIOL ESTER DERIVATIVE PRECURSOR DRUGFebruary 2023July 2025Allow2900NoNo
18106242PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USEFebruary 2023October 2025Allow3201YesNo
18159447ALKYLAMINE-SUBSTITUTED PERTHIOCARBAMATES AS DUAL PRECURSORS TO HYDROPERSULFIDE AND CARBONYL SULFIDEJanuary 2023December 2023Abandon1101NoNo
18100330SYNTHESIS OF ESUBERAPROST PRODRUGSJanuary 2023July 2024Allow1800NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHAMEEM, GOLAM M.

Strategic Value of Filing an Appeal

Total Appeal Filings
5
Allowed After Appeal Filing
5
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
95.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SHAMEEM, GOLAM M - Prosecution Strategy Guide

Executive Summary

Examiner SHAMEEM, GOLAM M works in Art Unit 1621 and has examined 892 patent applications in our dataset. With an allowance rate of 96.6%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner SHAMEEM, GOLAM M's allowance rate of 96.6% places them in the 87% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SHAMEEM, GOLAM M receive 0.72 office actions before reaching final disposition. This places the examiner in the 5% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SHAMEEM, GOLAM M is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +4.4% benefit to allowance rate for applications examined by SHAMEEM, GOLAM M. This interview benefit is in the 28% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 46.3% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 85.4% of cases where such amendments are filed. This entry rate is in the 97% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 32.1% are granted (fully or in part). This grant rate is in the 19% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 33.4% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.3% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.